Research programme: sulindac derivative - Medicon/Stony Brook University

Drug Profile

Research programme: sulindac derivative - Medicon/Stony Brook University

Alternative Names: MDC-922

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Medicon; State University of New York at Stony Brook
  • Class Indenes; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclo-oxygenase 1 modulators; Cyclo-oxygenase 2 modulators; Mitogen-activated protein kinase modulators; NF-kappa B modulators; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
  • 21 Apr 2010 Early research in Cancer in USA (unspecified route)
  • 21 Apr 2010 Pharmacodynamics data from in vitro trials in Cancer presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top